December 6, 2024 8:24am
Ain’t looking good in aftermarket and pre-open; employers indicated caution about the future pace of hiring although could provide a look of where the cell and gene therapy sector will be affected
Revisions may also make it harder to confidently interpret non-farm data.
- Nonfarm payrolls were expected to increase 214,000 in November, compared to an upwardly revised 36,000 in October and the Dow Jones consensus estimate for 214,000. The unemployment rate, however, edged higher to 4.2%, as expected.A broader measure that includes discouraged workers and those holding part-time jobs for economic reasons edged higher to 7.8%.
I say today what others won't, so you can do what others can't by sticking to the FACTS!
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Thursday’s night’s … RegMed Investors (RMi) Closing Bell: more econs while sector sentiment slips again … https://www.regmedinvestors.com/articles/13723
Friday: The pre-open Dow futures are UP +0.05% or (+24 points), the S&P futures are UP +0.08% or (+5 points) and the Nasdaq futures are UP +0.16% or (-34 points)
- Stock futures were lean yet positive (post non-farm payrolls) near the flatline Friday,
- European markets traded higher,
- Asia-Pacific markets traded mixed.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
- Indexes closed Thursday’s session lower, retreating from records the major indexes hit in the previous session.
- The week to date, the S&P 500 is up 0.7%, while the Nasdaq has gained 2.5%. The Dow was down 0.3%.
Economic Data Docket: Nonfarm payrolls, November (+200,000 expected, +12,000 previously); Unemployment rate, November (4.2% expected, 4.1% previously); Average hourly earnings, month-over-month, November (+0.3% expected, +0.4% previously); Average hourly earnings, year-over-year, November (+3.9% expected, +4% previously); Average weekly hours worked, November (34.3 expected, 34.3 previously); Labor force participation rate, November (62.6% previously)
Q4/24: 3 negative and 1 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Not taking any position ...
The BOTTOM LINE: Almost the weekend, “I remain a skeptic, as electronic trading remains the impetus to, I believe a cell and gene therapy sector getting artificial low” … as proven in past sessions”!
Trending or bending? …. A little bit of each!
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Portfolio managers are addressing rotations as December “shakes” to years-end.
- I keep writing about uncertainty and skepticism … and coming realities.
- Even with the potential for some market hiccups along the way, the good news is Q4 has historically skewed positively, even as sector earnings kicked the bucket down the road!
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
